CLARITIN HIVES RELIEF Drug Patent Profile
✉ Email this page to a colleague
When do Claritin Hives Relief patents expire, and what generic alternatives are available?
Claritin Hives Relief is a drug marketed by Bayer Healthcare Llc and is included in three NDAs.
The generic ingredient in CLARITIN HIVES RELIEF is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty suppliers are listed for this compound. Additional details are available on the loratadine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Claritin Hives Relief
A generic version of CLARITIN HIVES RELIEF was approved as loratadine by PLD ACQUISITIONS LLC on January 21st, 2003.
Summary for CLARITIN HIVES RELIEF
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 148 |
Clinical Trials: | 27 |
Patent Applications: | 3,920 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CLARITIN HIVES RELIEF at DailyMed |
Recent Clinical Trials for CLARITIN HIVES RELIEF
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Andover Research Eye Institute | Phase 4 |
Rutgers, The State University of New Jersey | Early Phase 1 |
National Cancer Institute (NCI) | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for CLARITIN HIVES RELIEF
US Patents and Regulatory Information for CLARITIN HIVES RELIEF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare Llc | CLARITIN HIVES RELIEF | loratadine | SYRUP;ORAL | 020641-003 | Nov 19, 2003 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer Healthcare Llc | CLARITIN HIVES RELIEF | loratadine | TABLET;ORAL | 019658-003 | Nov 19, 2003 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer Healthcare Llc | CLARITIN HIVES RELIEF REDITAB | loratadine | TABLET, ORALLY DISINTEGRATING;ORAL | 020704-003 | Nov 19, 2003 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CLARITIN HIVES RELIEF
See the table below for patents covering CLARITIN HIVES RELIEF around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 7186281 | ⤷ Try a Trial | |
Cyprus | 1405 | NOVEL ANTIHISTAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ⤷ Try a Trial |
Germany | 3573600 | ⤷ Try a Trial | |
Canada | 2333528 | SIROP A ANTIHISTAMINES STABILISE CONTENANT UN STABILISANT ACIDE AMINOPOLYCARBOXYLIQUE (A STABILIZED ANTIHISTAMINE SYRUP CONTAINING AMINOPOLYCARBOXYLIC ACID AS STABILIZER) | ⤷ Try a Trial |
Netherlands | 300042 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CLARITIN HIVES RELIEF
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0152897 | C00152897/01 | Switzerland | ⤷ Try a Trial | FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
0152897 | 2001C/013 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115 |
1110543 | SPC/GB08/005 | United Kingdom | ⤷ Try a Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022. |
0152897 | SPC/GB01/012 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115 |
1110543 | 08C0004 | France | ⤷ Try a Trial | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |